SCHEMBL4415858

SCHEMBL4415858

CCCOc1cccc(CN2CC3C(CNc4ccc(N5CCOCC5)c(F)c4)C3C2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.42
DRD2 P14416 2/20 0.41
HTR1A P08908 1/20 0.41
HTR2B P41595 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.39
HRH3 Q9Y5N1 3/20 0.38
DRD4 P21917 1/20 0.38
DRD3 P35462 1/20 0.38
EPHX2 P34913 2/20 0.38
MAPT P10636 2/20 0.37
POLB P06746 1/20 0.37
TSHR P16473 1/20 0.36
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 2/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
MMP1 P03956 1/20 0.36
MMP9 P14780 1/20 0.36
MMP13 P45452 1/20 0.36
ADAM17 P78536 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2179983 0.93 KDM4E (0.42) FAAHDRD2HTR1AHTR2BL3MBTL1
SCHEMBL4413306 0.91 L3MBTL1 (0.49) FAAHHTR1AHTR2BL3MBTL1HRH3
SCHEMBL4425285 0.90 KDM4E (0.43) FAAHMAPTPOLBALDH1A1KDM4E
SCHEMBL4414138 0.87 KDM4E (0.52) FAAHL3MBTL1MAPTALDH1A1KDM4E
SCHEMBL4412004 0.87 KCNH2 (0.46) DRD2DRD4EPHX2MAPTALDH1A1
SCHEMBL4424484 0.85 LMNA (0.41) L3MBTL1MAPTALDH1A1KDM4EHPGD
SCHEMBL4415853 0.85 FAAH (0.48) FAAHL3MBTL1EPHX2MAPTPOLB
SCHEMBL4419245 0.84 NPC1 (0.46) L3MBTL1MAPTTSHRALDH1A1KDM4E
SCHEMBL6506969 0.84 ALDH1A1 (0.50) L3MBTL1HRH3MAPTPOLBALDH1A1
SCHEMBL4412123 0.82 L3MBTL1 (0.41) L3MBTL1MAPTALDH1A1HTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
EP-1680124-A4 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2009-05-13 EP claimed
JP-2007508374-A 2007-04-05 JP claimed
EP-1680124-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS Pfizer Products Incorporated (US) 2006-07-19 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
WO-2005037216-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PRODUCTS INC. (US) 2005-04-28 WO claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 FAAH 2866/4885DRD2 61/4885HTR1A 236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.